Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05325866 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
A Phase 1 study of Solid Tumors, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 260
- Enrollment target
- 20
- Study locations
NCT05325866 is a Phase 1 study of Solid Tumors that has completed, run by Amgen. The registered enrollment target is 260 participants, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target. The trial reports 20 study locations across 11 states.
The verdict
NCT05325866, a Phase 1 study of Solid Tumors, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 260 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
Conditions Studied
Interventions
- DRUG Bemarituzumab
Study Locations (20)
Texas
- Texas Oncology - Dallas Fort Worth - Dallas
- University of Texas MD Anderson Cancer Center - Houston
- US Oncology Research Investigational Products Center - Irving
- Texas Oncology Northeast Texas - Tyler
Buenos Aires
- Instituto Alexander Fleming - Capital Federal
- Hospital Aleman - Ciudad Autonoma de Buenos Aires
- Fundacion Cenit Para La Investigacion - Ciudad Autonoma de Buenos Aires
- Hospital Italiano de La Plata - La Plata
New South Wales
- Liverpool Hospital - Liverpool
- Prince of Wales Hospital - Randwick
- Wollongong Hospital - Wollongong
California
- City of Hope National Medical Center - Duarte
- University of California Irvine - Orange
Colorado
- Rocky Mountain Cancer Centers - Aurora
Indiana
- Community Health Network MD Anderson Cancer Center - North - Indianapolis
Michigan
- Henry Ford Hospital - Detroit
Tennessee
- United States Oncology Regulatory Affairs Corporate Office - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2022-09-23 |
| Est. Completion | 2026-01-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05325866
The ClinicalTrials.gov registry entry for NCT05325866 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Bemarituzumab is the first listed.
NCT05325866 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Texas, Buenos Aires, New South Wales.
Frequently Asked Questions
What is clinical trial NCT05325866 about?
NCT05325866 is a clinical study titled "A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression". The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
What is the current status of trial NCT05325866?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2022-09-23. Estimated completion is 2026-01-28.
What conditions does trial NCT05325866 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT05325866?
The interventions under investigation include: Bemarituzumab (DRUG).
Who is sponsoring clinical trial NCT05325866?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05325866 being conducted?
This trial has 20 study locations across California, Colorado, Indiana, Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.